Perimenopause and Depression: What's Hormonal vs. Psychiatric?

By Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho

A 44-year-old woman comes to my office. She's been struggling with depression for the past 18 months — low mood, irritability, poor sleep, difficulty concentrating, loss of interest in things she used to enjoy. Her primary care doctor prescribed an SSRI six months ago. It helped a little at first, but she's still not herself.

She also mentions, almost as an aside: her periods have become irregular. She's been having hot flashes at night. Her libido has dropped. She feels like her brain doesn't work the way it used to.

This is a story I hear regularly. And the critical question — one that changes the entire treatment approach — is this: Is her depression a psychiatric condition that happens to be occurring during perimenopause, or is it a hormonal condition that is causing her depression?

The answer, in most cases, is the latter. And that means antidepressants alone are unlikely to fully resolve it.

Perimenopause is the transitional phase leading up to menopause — the point at which a woman has gone 12 consecutive months without a menstrual period. Perimenopause typically begins in the mid-to-late 40s, though it can start as early as the late 30s, and lasts an average of 4–8 years.

During perimenopause, ovarian function becomes erratic. Estrogen and progesterone levels fluctuate unpredictably — sometimes surging, sometimes plummeting — before eventually declining to the low, stable levels of menopause. It's this fluctuation, more than the eventual low levels, that drives many of the symptoms women experience.

Common perimenopausal symptoms include:

• Irregular periods
• Hot flashes and night sweats
• Sleep disruption
• Mood changes — irritability, anxiety, depression
• Brain fog and memory difficulties
• Decreased libido
• Vaginal dryness
• Joint pain
• Weight changes

The mood symptoms — particularly depression and anxiety — are among the most disruptive and the most frequently undertreated.

The data is striking. Women are 2–4 times more likely to develop a major depressive episode during perimenopause than at other times in their reproductive lives, even if they have no prior history of depression.

A landmark study from the Harvard Study of Moods and Cycles found that women with no prior history of depression were twice as likely to develop significant depressive symptoms during perimenopause compared to premenopausal women. The risk was highest during the late perimenopause transition.

Another large study, the Penn Ovarian Aging Study, followed women for over a decade and found that the perimenopausal transition was associated with a 2.5-fold increase in the risk of high depressive symptom scores, independent of prior depression history, life stress, and other confounders.

This is not a small effect. Perimenopause is one of the most significant risk periods for depression in a woman's life — and it's one that the mental health system is poorly equipped to address.

The mechanisms are multiple and interconnected.

Estrogen has profound effects on the serotonin system — the neurotransmitter system that most antidepressants target. Estrogen:

• Increases the synthesis of serotonin
• Upregulates serotonin receptors
• Inhibits the reuptake of serotonin (similar to how SSRIs work)
• Increases the sensitivity of serotonin receptors to stimulation

When estrogen fluctuates and eventually declines during perimenopause, serotonin signaling becomes dysregulated. This is why perimenopausal depression often has a different quality than typical depression — it's frequently accompanied by irritability, anxiety, and emotional reactivity rather than the classic "low and slow" presentation.

Estrogen also modulates the dopamine system, which governs motivation, pleasure, and reward. Declining estrogen reduces dopamine activity in the prefrontal cortex and limbic system, contributing to anhedonia (loss of pleasure), low motivation, and the "flatness" that many perimenopausal women describe.

Progesterone is metabolized into allopregnanolone, a potent positive modulator of GABA-A receptors — the same receptors targeted by benzodiazepines and alcohol. Allopregnanolone has anxiolytic, sedative, and mood-stabilizing effects.

During perimenopause, progesterone levels become erratic and eventually decline. This reduces allopregnanolone levels, leading to increased anxiety, sleep disruption, and mood instability. Women who are particularly sensitive to progesterone fluctuations — including those with a history of premenstrual dysphoric disorder (PMDD) — are at especially high risk.

Night sweats and hot flashes disrupt sleep architecture, reducing slow-wave sleep and REM sleep. Chronic sleep disruption is itself a major driver of depression, anxiety, and cognitive impairment. In perimenopausal women, the sleep disruption and the mood disruption are often inseparable.

Estrogen modulates the hypothalamic-pituitary-adrenal (HPA) axis — the body's stress response system. Declining estrogen can lead to HPA axis dysregulation, resulting in abnormal cortisol patterns, heightened stress reactivity, and increased vulnerability to depression.

This is the critical clinical point: if perimenopausal depression is primarily driven by hormonal dysregulation, then treating it with antidepressants alone is addressing the downstream effect while ignoring the upstream cause.

SSRIs and SNRIs work by increasing serotonin (and norepinephrine) availability in the synapse. But if the problem is that estrogen decline has reduced serotonin synthesis, receptor density, and receptor sensitivity, then boosting serotonin reuptake inhibition provides only partial compensation.

This is why many perimenopausal women report that antidepressants "take the edge off" but don't fully restore their mood, energy, and cognitive function. The hormonal substrate is still dysregulated.

A 2001 study by Soares et al. published in Archives of General Psychiatry found that transdermal estradiol was significantly more effective than placebo for perimenopausal depression — with response rates comparable to antidepressants. Importantly, this study specifically enrolled women with perimenopausal depression, not postmenopausal women.

More recent research has confirmed that hormone therapy — particularly estradiol — is an effective treatment for perimenopausal depression, especially in women who have not responded adequately to antidepressants.

In clinical practice, several features suggest that depression is primarily hormonally driven:

Timing: Depression that begins during perimenopause, particularly in a woman with no prior psychiatric history, is more likely to be hormonal.

Symptom pattern: Perimenopausal depression often features prominent irritability, anxiety, emotional reactivity, and cognitive symptoms (brain fog, memory difficulties) alongside low mood. Classic psychiatric depression tends to be more uniformly low.

Correlation with hormonal symptoms: If mood symptoms fluctuate with hot flashes, night sweats, and sleep disruption — or if they're worse in the luteal phase of the menstrual cycle — hormonal drivers are likely prominent.

Poor response to antidepressants: Women whose depression has not responded adequately to one or more antidepressants during perimenopause should be evaluated for hormonal contributors.

Lab findings: While hormone levels alone don't diagnose perimenopausal depression, elevated FSH, declining estradiol, and low progesterone in the context of mood symptoms support a hormonal etiology.

Effective treatment of perimenopausal depression typically requires addressing both the hormonal and psychological dimensions.

For women with perimenopausal depression, estradiol therapy — typically delivered via patch, gel, or pellet — is often the most effective intervention. Transdermal estradiol avoids first-pass liver metabolism and provides more stable blood levels than oral estrogen.

Progesterone (or progestogen) is added for women with an intact uterus to protect the uterine lining. Micronized progesterone (Prometrium) is generally preferred over synthetic progestins because it has more favorable effects on mood and sleep.

For women who are not candidates for hormone therapy or who prefer to avoid it, other options include:

• SSRIs/SNRIs: Can be helpful, particularly for hot flashes and mood, though often insufficient alone
• Gabapentin: Effective for hot flashes and sleep disruption
• Clonidine: Can reduce hot flash frequency

Treating sleep disruption is essential. Strategies include:

• Hormone therapy (often dramatically improves sleep by reducing night sweats)
• Cognitive behavioral therapy for insomnia (CBT-I)
• Sleep hygiene optimization
• Melatonin or low-dose doxepin for sleep maintenance

Cognitive behavioral therapy and mindfulness-based approaches are effective adjuncts for perimenopausal depression. They help women develop coping strategies, challenge negative thought patterns, and navigate the psychological dimensions of the menopausal transition — including identity shifts, relationship changes, and existential concerns.

For women with treatment-resistant perimenopausal depression — those who have not responded adequately to hormone therapy and antidepressants — ketamine therapy is an important option. Ketamine's rapid antidepressant effects are independent of the serotonin system, making it effective even when hormonal dysregulation has compromised serotonin signaling.

At Roth Family Medicine, we have treated a number of perimenopausal women with ketamine therapy, often in combination with hormone optimization, with excellent results.

Perimenopausal depression is common, underrecognized, and frequently undertreated. The key insight is that it is often primarily a hormonal condition — not a psychiatric one — and treating it as such changes the entire approach.

If you're a woman in your 40s or early 50s who is struggling with depression, anxiety, brain fog, or mood instability, and you're also experiencing irregular periods, hot flashes, or sleep disruption, please don't accept "try another antidepressant" as the only answer. A comprehensive hormonal evaluation and an integrated treatment approach may make all the difference.

Roth Family Medicine and Mental Health offers comprehensive hormone evaluation and treatment for perimenopausal women in Pocatello and throughout Southeast Idaho.

Book online: ZocDoc Call us: 208-904-4705 Location: 444 Hospital Way, Suite 422, Pocatello, Idaho 83201

Kyle Roth, FNP-BC, APRN, MSN, MHA is a board-certified family nurse practitioner specializing in hormone therapy, treatment-resistant depression, and integrative mental health care at Roth Family Medicine and Mental Health in Pocatello, Idaho.